RetinalGeniX Technologies Inc. announced that it has contracted with Avania CRO to provide guidance for the Company?s interactions with the FDA for the development of RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD) and RTG-2024 for the treatment of Alzheimer?s syndrome dementia, and the RetinalCam? image visualization device. Overall, RetinalGeniX now has advisors for each of its three components of precision ophthalmology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 USD | +12.90% | -.--% | +13.27% |
1st Jan change | Capi. | |
---|---|---|
+13.27% | 62.51M | |
+25.83% | 47.96B | |
+45.38% | 41.47B | |
+0.69% | 42.45B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- RTGN Stock
- News RetinalGenix Technologies Inc.
- RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device